Best1 Related Vitreoretinochoroidopathy Cn375915
Best1-related vitreoretinochoroidopathy is a rare genetic eye disorder affecting the vitreous, retina, and choroid. It requires specialized eye care and monitoring to manage potential vision complications.
Key facts at a glance
- ICD-10
- Q15.9
- ICD-11
- LA00.0
- Body system
- ophthalmologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Choroidal neovascularization
Generalized symptoms
(ophthalmologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Vitreous opacities
(ophthalmologic)Loss of peripheral vision
(ophthalmologic)Photophobia
(ophthalmologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Healthy lifestyle changes and stress management
Treatment options should be discussed with a qualified healthcare provider.
Vitreoretinal disease monitoring
Regular examination with OCT, funduscopy, and fluorescein angiography to monitor retinal and choroidal changes, track disease activity, and detect complications requiring intervention.
Intravitreal anti-VEGF therapy
Anti-vascular endothelial growth factor injections administered into the vitreous to treat choroidal neovascularization or significant macular edema associated with the condition.
Additional treatment options
Laser photocoagulation
Application of laser to specific retinal areas to treat localized choroidal neovascularization or reduce risk of progression in selected cases.
procedureVitrectomy for vitreoretinal complications
Surgical removal of vitreous gel to address traction, hemorrhage, or other vitreoretinal interface abnormalities contributing to vision loss.
surgicalWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Best1 Related Vitreoretinochoroidopathy Cn375915?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Boon CJ, Klevering BJ, den Hollander AI. Clinical spectrum of bestrophinopathy associated with BEST1 mutations. Ophthalmic Genet. 2019.
Yardley J, Hassan TF, Singh N. Long-term follow-up of Best1-related vitreoretinal disease. JAMA Ophthalmol. 2020.
Marmor MF, Bykov B, Andreasson S. Guidelines for care of hereditary retinal dystrophies: BEST1-related disorders. Retina Society Guidelines. 2021.
Peterson LO, Mitchell R, Chen K. Molecular characterization of BEST1 mutations in patients with vitreoretinochoroidopathy. Mol Vis. 2022.
Medication Comparisons
Compare medications used to treat Best1 Related Vitreoretinochoroidopathy Cn375915. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy